Tolerability and quality-of-life (QoL) results from the phase REGARD study: Ramucirumab versus placebo in patients with previously treated gastric or gastroesophageal junction (GEJ) adenocarcinoma

被引：0

作者：

Chau, I. ^{[1
]}

Passalacqua, R. ^{[2
]}

Zalcberg, J. R. ^{[3
,4
]}

Fuchs, C. S. ^{[5
,6
]}

Liepa, A. M. ^{[7
]}

Hsu, Y. ^{[8
]}

Schwartz, J. D. ^{[9
]}

Koshiji, M. ^{[10
]}

Tabernero, J. ^{[11
,12
]}

机构：

[1] Royal Marsden Hosp, Dept Med, Sutton, Surrey, England

[2] Ist Ospitalieri Cremona, Div Med Oncol, Cremona, Italy

[3] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[4] Univ Melbourne, Div Hematol & Med Oncol, Melbourne, Vic, Australia

[5] Dana Farber Canc Inst, Boston, MA 02115 USA

[6] Harvard Univ, Sch Med, Dept Med Oncol, Boston, MA USA

[7] Eli Lilly & Co, Global Hlth Outcomes, Indianapolis, IN 46285 USA

[8] ImClone Syst LLC, Global Stat Sci, Bridgewater, MA USA

[9] ImClone Syst LLC, Global Med Sci, Bridgewater, MA USA

[10] Eli Lilly & Co, Global Med Sci, Indianapolis, IN 46285 USA

[11] Vall dHebron Univ Hosp, Barcelona, Spain

[12] Univ Autonoma Barcelona, Dept Med Oncol, E-08193 Barcelona, Spain

来源：

EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2588

引用

页码：S615 / S615

页数：1

共 50 条

[31] MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+gastric or gastroesophageal junction adenocarcinoma-Trial in Progress
Strickler, John H.
Nakamura, Yoshiaki
Yoshino, Takayuki
Catenacci, Daniel V. T.
Janjigian, Yelena Y.
Barzi, Afsaneh
Bekaii-Saab, Tanios S.
Lenz, Heinz-Josef
Lee, Jeeyun
Van Cutsem, Eric
Chung, Hyun Cheol
Alsina, Maria
Siena, Salvatore
Mayor, Joal Garrido
Palanca-Wessels, Maria Corinna
Feng Wentao
Marshall, John
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[32] Interim safety and clinical activity in patients (pts) with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase I study of ramucirumab (R) plus durvalumab (D).
Bang, Yung-Jue
Golan, Talia
Lin, Chia-Chi
Kang, Yoon-Koo
Wainberg, Zev A.
Wasserstrom, Heather
Jin, Jin
Mi, Gu
McNeely, Samuel
Laing, Naomi
Goff, Laura Williams
Fu, Siqing
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
[33] MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+gastric or gastroesophageal junction adenocarcinoma (GEC): Trial in progress
Catenacci, D. V.
Strickler, J. H.
Shitara, K.
Nakamura, Y.
Janjigian, Y. Y.
Barzi, A.
Bekaii-Saab, T.
Lenz, H. J.
Chung, H. C.
Tabernero, J.
Yoshino, T.
Siena, S.
Mayor, J. G.
Palanca-Wessels, M. C.
Xie, D.
Marshall, J. L.
[J]. ANNALS OF ONCOLOGY, 2021, 32 : S1071 - S1072
[34] Predictive value of circulating VEGF in patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma treated with cetuximab in combination with cisplatin and docetaxel (Italian phase II DOCETUX Study)
Di Fabio, F.
Pinto, C.
Bucca, E.
Giaquinta, S.
Fabricio, A. S.
Mutri, V.
Michilin, S.
Llimpe, F. L. Rojas
Funaioli, C.
Gion, M.
Martoni, A. A.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[35] Phase II study of cetuximab in combination with folfiri as first-line treatment in patients with unresectable/metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: Preliminary results (FOLCETUX study)
Pinto, C.
Di Fabio, F.
Siena, S.
Cascinu, S.
Rojas Llimpe, F. L.
Ceccarelli, C.
Mutri, V
Giaquinta, S.
Piana, E.
Martoni, A. A.
[J]. ANNALS OF ONCOLOGY, 2006, 17 : XI54 - XI55
[36] Preliminary result of phase 1/2 study of ramucirumab plus nivolumab in patients with previously treated advanced gastric adenocarcinoma (NivoRam study).
Takahari, Daisuke
Shoji, Hirokazu
Hara, Hiroki
Esaki, Taito
Machida, Nozomu
Nagashima, Kengo
Aoki, Kazunori
Honda, Kazufumi
Miyamoto, Takahiro
Boku, Narikazu
Kato, Ken
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[37] Cetuximab in combination with folfiri as first-line treatment in patients with unresectable/metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: Preliminary results of folcetux phase II study
Di Fabio, Francesca
Pinto, Carmine
Siena, Salvatore
Cascinu, Stefano
Ceccarelli, Claudio
Llimpe, Fabiola Lorena Rojas
Mutri, Vita
Giaquinta, Stefania
Piana, Edera
Martoni, Andrea Angelo
[J]. ANNALS OF ONCOLOGY, 2006, 17 : 309 - 310
[38] Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.
Tabernero, Josep
Van Cutsem, Eric
Bang, Yung-Jue
Fuchs, Charles S.
Wyrwicz, Lucjan
Lee, Keun Wook
Kudaba, Iveta
Garrido, Marcelo
Chung, Hyun Cheol
Salguero, Hugo Raul Castro
Mansoor, Wasat
Braghiroli, Maria Ignez Freitas Melro
Goekkurt, Eray
Chao, Joseph
Wainberg, Zev A.
Kher, Uma
Shah, Sukrut
Kang, SoonMo Peter
Shitara, Kohei
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (18)
[39] A randomized, double-blind, placebo-controlled phase III study of cisplatin plus a fluoropyrimidine with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (RAINFALL, NCT02314117).
Fuchs, Charles S.
Tabernero, Josep
Al-Batran, Salah-Eddin
Chau, Ian
Ilson, David H.
Van Cutsem, Eric
Shitara, Kohei
Ferry, David
Emig, Michael
Vanvoorden, Veerle
Hsu, Yanzhi
Xu, Yihuan
Sashegyi, Andreas
Das, Mayukh
Shah, Manish A.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
[40] Phase II study of cetuximab plus FOLFIRI as first-line treatment in patients with unresectable/metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (FOLCETUX study): Preliminary results.
Pinto, C.
Di Fabio, F.
Siena, S.
Cascinu, S.
Llimpe, F. L. Rojas
Ceccarelli, C.
Mutri, V.
Giaquinta, S.
Piana, E.
Martoni, A. A.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 186S - 186S

← 1 2 3 4 5 →